Vogenx Inc. (VOGX)
NasdaqCM: VOGX
· Real-Time Price · USD
15.75
+0.97 (6.56%)
At close: Aug 18, 2026, 9:53 AM
Vogenx Inc. (VOGX) Stock Price, Analysis & Data
6.56% (1D)
| Bid | n/a |
| Market Cap | 219.01M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.56M |
| Beta | n/a |
| EPS (ttm) | -0.2 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | -59.21 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | 31,467 |
| Avg. Volume (20D) | 267,400 |
| Open | 14.80 |
| Previous Close | 14.78 |
| Day's Range | 14.80 - 16.26 |
| 52-Week Range | 12.95 - 16.65 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VOGX
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorpora...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 12, 2026
Employees 4
Stock Exchange NasdaqCM
Ticker Symbol VOGX
Website https://vogenx.com
Financial Performance
In 2025, Vogenx's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -1.45M, a decrease of -34.4%.
Financial Statements